The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Understanding The Physiological Consequences Of Biased Signalling Mediated By The Glucagon-like Peptide-1 Receptor
Funder
National Health and Medical Research Council
Funding Amount
$636,508.00
Summary
The glucagon-like peptide 1 receptor is a major target for treatment of Type 2 diabetes and obesity. However, the development of drugs targeting this receptor is challenging as activation by different ligands can result in distinct signalling biases, a paradigm for which there is limited understanding of the physiological consequences. This project will address this critical knowledge gap and may allow for development of novel drugs with improved therapeutic outcomes.
Purinergic P2X7 Receptor As A Target For Antidepressant Drug Discovery
Funder
National Health and Medical Research Council
Funding Amount
$567,760.00
Summary
Depression is the most common mental disease. Around one million Australian adults and 100,000 young people live with depression each year resulting in significant economic, social and personal costs. Despite multiple treatments of depression, there are still several serious unmet needs with most current antidepressants showing limited effectiveness. We have identified a novel protein in the brain that represents an innovative approach to providing a platform for antidepressant drug discovery.